Phase 2 N=6 Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma
Glioblastoma
Primary: Number of Dose Limiting Toxicities — 0 Events meeting DLT Criteria
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=107 Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
Solid Tumors · Non-small Cell Lung Cancer · Castration Resistant Prostate Cancer
Primary: Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 3.9; 1.9 Percentage of participants
Phase 2 N=122 Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Any Solicited Administration Site Adverse Events (AEs) — 1; 6; 5; 21 Participants
Phase 2 N=294 Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
Psoriasis
Primary: Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 — -1.6; -2.2; -1.4; -2.2 Unit on a scale — p=0.1641
Phase 2 N=83 Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
Diabetic Nephropathy
Primary: Ratio to Baseline in Urinary Albumin to Creatinine Ratio (UACR) — 0.90; 1.06; 0.83; 1.00 Ratio to baseline
Phase 2 N=30 Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm
Parkinson Disease
Primary: Postural Instability and Gait Disorder (PIGD) Score — 4.625; 4.625; 4.23; 4.09 score on a scale — p=0.0407
Phase 2 N=25 Evaluate SAGE-547 in Participants With Essential Tremor
Essential Tremor
Primary: Stage 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 12.0; 20.0; 0; 0 percentage of participants
Phase 2 N=462 Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
Moderate to Severe Atopic Dermatitis
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Clinical Score at Week 16 — -57.589; -56.734; -38.099; -42.142 percentage change — p== 0.008
Phase 2 N=72 A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
B-Cell Malignancies
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 1; 3; 3; 32 Participants
Phase 2 N=72 A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus
Respiratory Syncytial Virus Infections
Primary: Area Under the Respiratory Syncytial Virus (RSV) Viral Load (VL)-Time Curve (AUC) From Immediately Prior to First Dose of Study Drug (Baseline) Through Day 3 — 207.3…
Phase 2 N=35 Neuroimaging Reward, Behavioral Treatment, and Smoking Cessation
Smoking
Primary: Change in BOLD (Blood-oxygen-level-dependent) Response to Monetary Reward — -0.085; -0.067 fMRI BOLD signal — p=0.891
Phase 2 N=68 EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
Lymphoma, AIDS-related · Lymphoma, Large B-Cell, Diffuse
Primary: Median Progression Free Survival (PFS) — 13.8 years
Phase 2 N=40 Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
Refractory or Recurrent Solid Tumors · Rhabdomyosarcoma · Non-Rhabdomyosarcoma Soft Tissue Sarcoma
Primary: Phase 1: Recommended Phase 2 Dose (RP2D) of Eribulin Mesilate in Combination With Irinotecan Hydrochloride — 1.4; 40 mg/m^2
Phase 2 N=71 Benfotiamine in Alzheimer's Disease: A Pilot Study
Alzheimer's Disease
Primary: Change From Baseline in ADAS-Cog Score — 1.39; 3.26 score on a scale — p=0.125
Phase 2 N=94 The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products
Nicotine Dependence, Cigarettes
Primary: Expired Air Carbon Monoxide (CO) to Assess Recent Smoking — 18.3; 22.9; 21.3; 25.6 Parts per million (ppm) — p=0.01